Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

ARYx Raises $55M To Fund Development Of Safer Drugs

June 2, 2004

By Aaron Lorenzo

More Of The Same: Alnylam Gets IPO Done, Below Range

June 1, 2004

By Aaron Lorenzo

More Of The Same: Alnylam Gets IPO Done, Below Range

June 1, 2004

By Aaron Lorenzo

Acadia, Critical Therapeutics Price In 'Not A Robust Market'

May 28, 2004

By Aaron Lorenzo

Two more biotech companies went public Thursday, but as has been the case lately, their offerings brought in less than first expected. (BioWorld Today)

Acadia, Critical Therapeutics Price In 'Not A Robust Market'

May 28, 2004

By Aaron Lorenzo

Two more biotech companies went public Thursday, but as has been the case lately, their offerings brought in less than first expected. (BioWorld Today)

Plexxikon Gets $15M Investment For Diabetes Drug Development

May 27, 2004

By Aaron Lorenzo

Plexxikon Gets $15M Investment For Diabetes Drug Development

May 27, 2004

By Aaron Lorenzo

ISTA Submits NDA For Xibrom As Eye Inflammation Treatment

May 26, 2004

By Aaron Lorenzo

ISTA Submits NDA For Xibrom As Eye Inflammation Treatment

May 26, 2004

By Aaron Lorenzo

Vertex Receives $21M From Affiliate Of CF Foundation

May 25, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...